Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

By sjmartinez • December 13, 2024

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 9:S2352-3018(24)00247-9. doi: 10.1016/S2352-3018(24)00247-9. Epub ahead of print. PMID: 39667379.

Tags: Infectious Diseases, Publications

The Cost and Intermediate Cost-Effectiveness of a Randomized Control Trial Delivering U=U Messaging to Increase HIV Testing Among South African Men

Smith PJ, Davey DJ, Schmucker L, Bekker LG, Medina-Marino A, Thirumurthy H, Buttenheim AM, Meyer-Rath G. The Cost and Intermediate Cost-Effectiveness of a Randomized Control[...]

Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges

Murdande S, Mishra S, Munoz A, Fox K, D'Assumpcao C. Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges. Infect Prev Pract. 2026[...]

Mpox seroprevalence among sex workers and men who have sex with men preceding sustained urban outbreak in the Democratic Republic of the Congo

Mukadi PK, Merritt S, Nkuba-Ndaye A, Halbrook M, Anta Y, Bodisa Matamu T, Hasivirwe Vakaniaki E, Mukadi-Bamuleka D, Harrigan RJ, Lunyanga L, Kacita C, Kompany[...]